Respiratory Syncytial Virus Infection: An Update

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Respiratory syncytial virus (RSV) is a primary cause of lower respiratory tract infections (LRTI) in infants.
• RSV affects all age groups but poses the greatest risk to children under one year old, particularly premature infants or those with underlying conditions.
• An increase in RSV incidence may be occurring post-COVID-19, potentially due to 'immunity debt'.

Purpose of the Study:

• To review the clinical presentation and management of RSV infections in children.
• To highlight recent advancements in RSV vaccine development and approvals.

Main Methods:

• Literature review of RSV epidemiology, clinical manifestations, and treatment modalities.
• Summary of recent clinical trial outcomes for RSV vaccines in adults and pregnant women.
• Inclusion of information on newly approved RSV vaccines for older adults.

Main Results:

• RSV infection presents with symptoms like fever, cough, and runny nose, potentially leading to severe conditions such as bronchiolitis or pneumonia.
• Supportive care, including oxygen therapy or mechanical ventilation for severe cases, is the primary management strategy.
• Two RSV vaccines (GSK's Arexvy and Pfizer's ABRYSVO) are now FDA-approved for use in older adults.

Conclusions:

• While most children recover from RSV within weeks, severe cases necessitate hospitalization and intensive supportive care.
• Promising RSV vaccine candidates have emerged, with recent approvals marking a significant step in preventative strategies for vulnerable populations, especially older adults.